Phase 1 Trial of Bortezomib Plus R-CHOP in Previously Untreated Patients With Aggressive Non-Hodgkin Lymphoma.

The article provides information on a study which determined the efficacy and safety of bortezomib in combination with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL). A review of the related literature on DLBCL and MCL is offered. It describes the methods utilized in the study. The occurrence of hematologic toxicities are recorded. It observes that bortezomib is feasible to be added to R-CHOP chemotherapy.